博宁对骨转移患者骨吸收标志的影响

Influence of Bonin on Bone Resorption Markers in Metastatic Bone Diseases

目的 :探讨博宁对骨转移患者骨吸收标志的影响。方法 :临床确诊为骨转移患者24例 ,一次性接受博宁90mg静点 ,观察治疗前及治疗后7天骨吸收标志的变化。结果 :治疗前尿钙、尿吡啶酚和脱氧吡啶酚较正常值分别为25 %、71 %和100 %患者升高。治疗后第7天尿钙、尿吡啶酚和脱氧吡啶酚较治疗前均明显下降(P<0 001) ,三项指标较治疗前分别下降了59 %、62%和60 % ,血钙治疗后也有明显下降(P<0 001) ,而血磷治疗前后无明显变化。治疗前后尿脱氧吡啶酚与尿钙均无明显相关性(P>0 05) ,而与尿吡啶酚在治疗前后均有明显的相关性(P<0 01)。结论 :博宁可使骨转移患者骨吸收标志明显下降 。

Purpose: To investigate the effects of Bonin on bone resorption markers in metastatic bone diseases Methods: Twenty-four patients with metastatic bone disease who did not receive any systemic antineoplastic therapy or bisphosphonate one month ago were studied Level of bone resorption markers were compared before treatment and on the seventh day after giving a single dose of 90mg Bonin infusion Results: The urinary levels of calcium (uCa), pyridinoline (uPYD) and deoxypyridinoline (uDPD) before Bonin treatment were 25%, 74%and 100%(higher than normal) respectively On the day 7 of Bonin treatment the urinary levels of calcium, pyridinoline and deoxypyridinoline were 59%,62%and 60%respectively which decreased significantly (P<0 001) Serum calcium also decreased significantly (P<0 001), but no marked change of serum phosphate before and after treatment The level of uCa did not correlate with the level of uDPD, whereas the correlation between uPYD and uDPD was significant (P<0 01) Conclusion: Bonin could induce significant decrease of bone resorption uPYD and uDPD may be useful for monitoring the therapeutic effect on bone metastatis in cancer patients